Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?

[1]  X. Shu,et al.  Circulating transforming growth factor-β-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study , 2008, Breast Cancer Research and Treatment.

[2]  R. Randall,et al.  Transforming Growth Factor β-Induced Smad1/5 Phosphorylation in Epithelial Cells Is Mediated by Novel Receptor Complexes and Is Essential for Anchorage-Independent Growth , 2008, Molecular and Cellular Biology.

[3]  R. Flavell,et al.  TGF-β: A Master of All T Cell Trades , 2008, Cell.

[4]  D. Notterman,et al.  Transforming Growth Factor-β Signaling Strength Determines Target Gene Expression Profile in Human Keratinocytes , 2008 .

[5]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[6]  Max S Wicha,et al.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Derynck,et al.  The type I TGF-β receptor is covalently modified and regulated by sumoylation , 2008, Nature Cell Biology.

[8]  K. Schlingensiepen,et al.  Preliminary results of a phase I/II study in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma using systemic i.v. administration of AP 12009 , 2008 .

[9]  J. Berzofsky,et al.  Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGF{beta}) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC) , 2008 .

[10]  J. Baselga,et al.  First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase , 2008 .

[11]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[12]  J. Berzofsky,et al.  An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. , 2008, Cancer research.

[13]  Aleksandra M. Michalowska,et al.  Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. , 2008, Cancer research.

[14]  M. Waltham,et al.  Epithelial mesenchymal transition traits in human breast cancer cell lines , 2008, Clinical & Experimental Metastasis.

[15]  E. Puré,et al.  Fibroblast migration is mediated by CD44-dependent TGFβ activation , 2008, Journal of Cell Science.

[16]  K. Horwitz,et al.  Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts , 2008, Proceedings of the National Academy of Sciences.

[17]  Richard A Flavell,et al.  Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. , 2008, Immunity.

[18]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[19]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.

[20]  M. Reiss,et al.  Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype. , 2008, Cancer research.

[21]  Brian Bierie,et al.  Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. , 2008, Cancer research.

[22]  W. Muller,et al.  Signaling through ShcA Is Required for Transforming Growth Factor β- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion , 2008, Molecular and Cellular Biology.

[23]  R. Campbell,et al.  Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. , 2008, Journal of medicinal chemistry.

[24]  You-yi Zhang,et al.  UNDERSTANDING THE ROLE OF TRANSFORMING GROWTH FACTOR‐β SIGNALLING IN THE HEART: OVERVIEW OF STUDIES USING GENETIC MOUSE MODELS , 2008, Clinical and experimental pharmacology & physiology.

[25]  N. Himes,et al.  VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma , 2008, The Journal of experimental medicine.

[26]  D. Carbone,et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. , 2008, Cancer cell.

[27]  J. Baselga,et al.  TGF-β signalling-related markers in cancer patients with bone metastasis , 2008 .

[28]  Richard A Flavell,et al.  ‘Yin–Yang’ functions of transforming growth factor‐β and T regulatory cells in immune regulation , 2007, Immunological reviews.

[29]  G. V. van Dongen,et al.  Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.

[30]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[31]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[32]  G. Bhanot,et al.  Analysis of breast cancer progression using principal component analysis and clustering , 2007, Journal of Biosciences.

[33]  M. Reiss,et al.  TGFβ superfamily signaling: notes from the desert , 2007 .

[34]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[35]  Y. Wan,et al.  Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy , 2007, Clinical Cancer Research.

[36]  M. Wicha,et al.  Cancer stem cells: implications for cancer treatment and prevention. , 2007, Cancer journal.

[37]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[38]  J. Pichler,et al.  Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies , 2007 .

[39]  M. Miller,et al.  Testicular Interstitial Cell Tumor and Gynecomastia in a Rabbit , 2007, Veterinary pathology.

[40]  Genee Y. Lee,et al.  The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.

[41]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[42]  C. Kuperwasser,et al.  Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? , 2007, Breast Cancer Research.

[43]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[44]  H. Moses,et al.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. , 2007, The Journal of clinical investigation.

[45]  H. Ishwaran,et al.  Lung metastasis genes couple breast tumor size and metastatic spread , 2007, Proceedings of the National Academy of Sciences.

[46]  Paula D. Bos,et al.  Mediators of vascular remodelling co-opted for sequential steps in lung metastasis , 2007, Nature.

[47]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[48]  M. Eichelbaum,et al.  TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells , 2007, Breast Cancer Research and Treatment.

[49]  G. Merlino,et al.  TGFβ1 and TGFα contrarily affect alveolar survival and tumorigenesis in mouse mammary epithelium , 2007 .

[50]  P. Bugert,et al.  Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk , 2007, Breast Cancer Research and Treatment.

[51]  M. Barcellos-Hoff,et al.  New rationales for using TGFbeta inhibitors in radiotherapy , 2007, International journal of radiation biology.

[52]  Y. Qian,et al.  Development and validation of a phosphorylated SMAD ex vivo stimulation assay , 2007, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[53]  K. Miyazono,et al.  Ki26894, a novel transforming growth factor‐β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line , 2007, Cancer science.

[54]  J. Mantil,et al.  Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma , 2006, Cancer Gene Therapy.

[55]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[56]  L. Wakefield,et al.  Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. , 2006, Human gene therapy.

[57]  Y. Shiloh,et al.  Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. , 2006, Cancer research.

[58]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[59]  N. Matsumoto,et al.  Recent progress in genetics of Marfan syndrome and Marfan-associated disorders , 2006, Journal of Human Genetics.

[60]  N. Senzer,et al.  Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Flavell,et al.  Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms , 2006 .

[62]  B. Teicher,et al.  TGF-β in cancer and as a therapeutic target , 2006 .

[63]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[64]  T. Hahn,et al.  Targeting transforming growth factor β to enhance cancer immunotherapy , 2006, Current oncology.

[65]  Larry Norton,et al.  Is cancer a disease of self-seeding? , 2006, Nature Medicine.

[66]  C. Arteaga,et al.  Inhibition of Transforming Growth Factor-β Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy , 2006, Clinical Cancer Research.

[67]  M. Reiss,et al.  Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo , 2006, Clinical Cancer Research.

[68]  Xiu-fen Lei,et al.  Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. , 2006, Cancer research.

[69]  Aleksandra M. Michalowska,et al.  Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. , 2006, Cancer research.

[70]  M. Barcellos-Hoff,et al.  Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression , 2006, Oncogene.

[71]  R. Akhurst.  Large- and small-molecule inhibitors of transforming growth factor-beta signaling. , 2006, Current opinion in investigational drugs.

[72]  R. Sheppard,et al.  Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmia , 2006, Immunology.

[73]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[74]  F. Bertucci,et al.  Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.

[75]  Richard A Flavell,et al.  Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.

[76]  F. Blanco,et al.  Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. , 2006, Clinical medicine & research.

[77]  S. Huet,et al.  Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. , 2006, Drug news & perspectives.

[78]  R. Campbell,et al.  Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. , 2006, Journal of medicinal chemistry.

[79]  R. Akhurst,et al.  TGFβ inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development , 2006, Journal of Cell Science.

[80]  Mary E. Choi,et al.  Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. , 2006, Cancer research.

[81]  P. ten Dijke,et al.  The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. , 2006, Cancer research.

[82]  M. Ramachandra,et al.  An oncolytic adenovirus expressing soluble transforming growth factor-β type II receptor for targeting breast cancer: in vitro evaluation , 2006, Molecular Cancer Therapeutics.

[83]  Brian Bierie,et al.  TGF- and cancer , 2006 .

[84]  C. Arteaga.  Inhibition of TGFβ signaling in cancer therapy , 2006 .

[85]  U. Bogdahn,et al.  Targeted tumor therapy with the TGF-β2 antisense compound AP 12009 , 2006 .

[86]  A. Benigni,et al.  Role of anti-TGF-β antibodies in the treatment of renal injury , 2006 .

[87]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[88]  A. Roberts,et al.  Smad4-expression is decreased in breast cancer tissues: a retrospective study , 2006, BMC Cancer.

[89]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Wei He,et al.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[92]  U. Bogdahn,et al.  Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. , 2005, Oligonucleotides.

[93]  J. Gauthier,et al.  Inhibition of TGF‐β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine‐induced liver fibrosis , 2005 .

[94]  M. Kolb,et al.  Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. , 2005, American journal of respiratory and critical care medicine.

[95]  D. Kögel,et al.  TGF-β1 activates two distinct type I receptors in neurons , 2005, The Journal of Cell Biology.

[96]  Ariel J. Levine,et al.  TGFβ/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells , 2005 .

[97]  Brian Bierie,et al.  Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. , 2005, Cancer research.

[98]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[99]  J. Chirgwin,et al.  Molecular mechanisms of breast cancer metastases to bone. , 2005, Clinical breast cancer.

[100]  S. A. Watkins,et al.  Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. , 2005, Biochemistry.

[101]  J. Ross,et al.  Effect of anti-TGF-beta antibodies in syngeneic mouse models of metastasis. , 2004, Journal of musculoskeletal & neuronal interactions.

[102]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[103]  Y. Kang.  Breast cancer bone metastasis: molecular basis of tissue tropism. , 2004, Journal of musculoskeletal & neuronal interactions.

[104]  R. Campbell,et al.  Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. , 2004, Bioorganic & medicinal chemistry letters.

[105]  M. Reiss,et al.  Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling. , 2004, Biochemical pharmacology.

[106]  C. Arteaga,et al.  Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell Motility* , 2004, Journal of Biological Chemistry.

[107]  J. Brugge,et al.  ErbB2 and TGF-beta: A Cooperative Role in Mammory Tumor Progression? , 2004, Cell cycle.

[108]  K. Rouschop,et al.  CD44 deficiency increases tubular damage but reduces renal fibrosis in obstructive nephropathy. , 2004, Journal of the American Society of Nephrology : JASN.

[109]  A. Roberts,et al.  SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. , 2004, Molecular pharmacology.

[110]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[111]  Joshua LaBaer,et al.  Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[112]  P. Fritz,et al.  Prognostic Significance of Transforming Growth Factor β Receptor II in Estrogen Receptor-Negative Breast Cancer Patients , 2004, Clinical Cancer Research.

[113]  M. O’Connor-McCourt,et al.  Expression of TGF‐β type II receptor antisense RNA impairs TGF‐β signaling in vitro and promotes mammary gland differentiation in vivo , 2003, International journal of cancer.

[114]  L. Wakefield,et al.  Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. , 2003, Cancer research.

[115]  Dana M. Brantley-Sieders,et al.  Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1 , 2003, Molecular and Cellular Biology.

[116]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[117]  L. Wakefield,et al.  TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression , 2003 .

[118]  M. Goumans,et al.  Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. , 2003, Trends in cardiovascular medicine.

[119]  Y. Shyr,et al.  Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. , 2003, The American journal of pathology.

[120]  J. Chirgwin,et al.  A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[121]  M. Vieth,et al.  Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. , 2003, Journal of medicinal chemistry.

[122]  P. Khaw,et al.  Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. , 2003, Investigative ophthalmology & visual science.

[123]  Weichung J Shih,et al.  Loss of Smad Signaling in Human Colorectal Cancer Is Associated with Advanced Disease and Poor Prognosis , 2003, Cancer journal.

[124]  A. Rademaker,et al.  Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. , 2003, Cancer research.

[125]  R. Cardiff,et al.  Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[126]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[127]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[128]  K. Mohammad,et al.  Role of endothelin‐1 in osteoblastic bone metastases , 2003, Cancer.

[129]  Justin P. Annes,et al.  Making sense of latent TGFβ activation , 2003, Journal of Cell Science.

[130]  S. Ledbetter,et al.  Minimal Effects on Immune Parameters Following Chronic Anti-TGF-β Monoclonal Antibody Administration to Normal Mice , 2003, Immunopharmacology and immunotoxicology.

[131]  L. Bourguignon,et al.  Hyaluronan Promotes Signaling Interaction between CD44 and the Transforming Growth Factor β Receptor I in Metastatic Breast Tumor Cells* , 2002, The Journal of Biological Chemistry.

[132]  Mary Helen Barcellos-Hoff,et al.  Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. , 2002, Cancer research.

[133]  Jamal Zweit,et al.  Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. , 2002, Journal of the National Cancer Institute.

[134]  L. Chodosh,et al.  Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. , 2002, Molecular endocrinology.

[135]  J. Otte,et al.  Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. , 2002, Genes & development.

[136]  F. López‐Casillas,et al.  Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. , 2002, Cancer research.

[137]  J. Chirgwin,et al.  Transforming Growth Factor-β Stimulates Parathyroid Hormone-related Protein and Osteolytic Metastases via Smad and Mitogen-activated Protein Kinase Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[138]  C. Arteaga,et al.  Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases , 2002 .

[139]  L. Wakefield,et al.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.

[140]  C. Knabbe,et al.  Antiestrogenic Regulation of Transforming Growth Factor Beta Receptors I and II in Human Breast Cancer Cells , 2002, Annals of the New York Academy of Sciences.

[141]  L. Wakefield,et al.  Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. , 2002, The American journal of pathology.

[142]  Jian Luo,et al.  Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells , 2002, Oncogene.

[143]  Richard Simon,et al.  Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[144]  E. Puré,et al.  Resolution of Lung Inflammation by CD44 , 2002, Science.

[145]  C. Deng,et al.  Smad3 in the mammary epithelium has a nonredundant role in the induction of apoptosis, but not in the regulation of proliferation or differentiation by transforming growth factor-beta. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[146]  J. Downward,et al.  Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis , 2002, The Journal of Cell Biology.

[147]  David L Rimm,et al.  Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. , 2002, Cancer research.

[148]  R. Cardiff,et al.  Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .

[149]  J Kuriyan,et al.  The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. , 2001, Molecular cell.

[150]  S. Sheen-Chen,et al.  Serum Levels of Transforming Growth Factor β1 in Patients With Breast Cancer , 2001 .

[151]  K. Flanders,et al.  Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? , 2001, Chest.

[152]  H. Vloedgraven,et al.  Monitoring Metastatic Behavior of Human Tumor Cells in Mice with Species‐Specific Polymerase Chain Reaction: Elevated Expression of Angiogenesis and Bone Resorption Stimulators by Breast Cancer in Bone Metastases , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[153]  D. Schmitt,et al.  Transforming growth factor‐β1 and ultraviolet A1 radiation increase production of vascular endothelial growth factor but not endothelin‐1 in human dermal fibroblasts , 2000 .

[154]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[155]  T. Guise.  Molecular mechanisms of osteolytic bone metastases , 2000, Cancer.

[156]  V. Kaartinen,et al.  Differential expression of TGF-β isoforms during postlactational mammary gland involution , 2000, Cell and Tissue Research.

[157]  J. Massagué,et al.  Controlling TGF-β signaling , 2000, Genes & Development.

[158]  Carlos L Arteaga,et al.  Transforming growth factor-β and breast cancer: Tumor promoting effects of transforming growth factor-β , 2000, Breast Cancer Research.

[159]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[160]  Simpson,et al.  Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in‐situ and invasive carcinomas , 2000, Histopathology.

[161]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[162]  W. Dupont,et al.  Transforming Growth Factor-β and Breast Cancer Risk in Women With Mammary Epithelial Hyperplasia. , 1999, Journal of the National Cancer Institute.

[163]  C. Heldin,et al.  TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. , 1999, Journal of cell science.

[164]  M. Reiss.  TGF- and cancer , 1999 .

[165]  Jeffrey B. Kopp,et al.  TGF- and fibrosis , 1999 .

[166]  L. Sun,et al.  A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. , 1999, Cancer research.

[167]  A. Green,et al.  Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. , 1999, International journal of oncology.

[168]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[169]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[170]  R. Clarke,et al.  Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. , 1999, Journal of the National Cancer Institute.

[171]  C. Arteaga,et al.  Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. , 1998, Experimental cell research.

[172]  H. Beug,et al.  TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis , 1998, Current Biology.

[173]  M. Barcellos-Hoff,et al.  How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. , 1998, Radiation research.

[174]  M. Reiss,et al.  Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.

[175]  L. Wakefield,et al.  Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency , 1998, Nature Medicine.

[176]  Hiroyuki Miyoshi,et al.  Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc Genes , 1998, Cell.

[177]  R. Derynck,et al.  Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[178]  P. Sminia,et al.  Plasma transforming growth factor beta levels in breast cancer patients. , 1998, Oncology reports.

[179]  Y. Nagamachi,et al.  Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers. , 1998, Oncology reports.

[180]  V. Müller,et al.  Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. , 1998, Cancer research.

[181]  P. V. van Diest,et al.  Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops , 1998, The Journal of pathology.

[182]  M. Barcellos-Hoff,et al.  Latent transforming growth factor β1 activation in situ: quantitative and functional evidence after low‐dose γ‐irradiation 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[183]  V. Jordan,et al.  Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. , 1996, British Journal of Cancer.

[184]  S. Yuspa,et al.  Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. , 1996, Cancer research.

[185]  J. Bartlett,et al.  Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. , 1996, British Journal of Cancer.

[186]  W. Jonat,et al.  Regulation and Role of TGFβ Production in Breast Cancer a , 1996 .

[187]  W. Jonat,et al.  Transforming Growth Factor β2 (TGF-β2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen , 1995 .

[188]  A. Guttmacher,et al.  Hereditary hemorrhagic telangiectasia. , 1995, The New England journal of medicine.

[189]  M. Anscher,et al.  Elevated Plasma Transforming Growth Factor-β1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor , 1995, Annals of surgery.

[190]  R. Coffey,et al.  Mammary tumor suppression by transforming growth factor beta 1 transgene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[191]  J. Foekens,et al.  Transforming growth factor beta secretion from primary breast cancer fibroblasts , 1995, Molecular and Cellular Endocrinology.

[192]  A. Balmain,et al.  Concerted action of TGF-beta 1 and its type II receptor in control of epidermal homeostasis in transgenic mice. , 1995, Genes & development.

[193]  R. Derynck,et al.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.

[194]  B. Katzenellenbogen,et al.  Alterations in Transforming Growth Factor-α and -β Production and Cell Responsiveness during the Progression of MCF-7 Human Breast Cancer Cells to Estrogen-Autonomous Growth , 1994 .

[195]  W. Border,et al.  Transforming Growth Factor β in Tissue Fibrosis , 1994 .

[196]  J. Bartlett,et al.  Expression of transforming growth factor beta mRNA isoforms in human breast cancer. , 1994, British Journal of Cancer.

[197]  B. Hogan,et al.  Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. , 1993, Genes & development.

[198]  Mahlon D. Johnson,et al.  Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. , 1993, The Journal of clinical investigation.

[199]  P. Dijke,et al.  Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells , 1993, Molecular and Cellular Endocrinology.

[200]  A. Greenberg,et al.  Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. , 1993, The American journal of pathology.

[201]  M. Sporn,et al.  Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[202]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[203]  T. Stukel,et al.  Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. , 1992, Cancer Research.

[204]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[205]  M. Sporn,et al.  Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. , 1992, Cancer research.

[206]  R. Walker,et al.  Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. , 1992, European journal of cancer.

[207]  M. Dietel,et al.  Induction of Transforming Growth Factor β by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF‐7 Cells , 1991, American journal of clinical oncology.

[208]  G. Nicolson,et al.  Coexpression of cytokeratins characteristic for myoepithelial and luminal cell lineages in rat 13762NF mammary adenocarcinoma tumors and their spontaneous metastases. , 1991, Cancer research.

[209]  V. Jordan,et al.  Growth Stimulation and Differential Regulation of Transforming Growth Factor-β1 (TGFβ1), TGFβ2, and TGFβ3 Messenger RNA Levels by Norethindrone in MCF-7 Human Breast Cancer Cells , 1991 .

[210]  C. Steel,et al.  Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. , 1991, British Journal of Cancer.

[211]  A. Manni,et al.  Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar , 1991, Breast Cancer Research and Treatment.

[212]  M. Nakajima,et al.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[213]  M. Sporn,et al.  Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. , 1990, British Journal of Cancer.

[214]  S. Bates,et al.  Production of and responsiveness to transforming growth factor-beta in normal and oncogene-transformed human mammary epithelial cells. , 1989, Cancer research.

[215]  G. Wilding,et al.  Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines , 1989 .

[216]  C. Osborne,et al.  Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells , 1988 .

[217]  T. Powles,et al.  Growth factor expression in normal, benign, and malignant breast tissue , 1988, British medical journal.

[218]  Sporn,et al.  Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. , 1988, The Journal of biological chemistry.

[219]  L M Wakefield,et al.  Distribution and modulation of the cellular receptor for transforming growth factor-beta , 1987, The Journal of cell biology.

[220]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.

[221]  M. Reiss.  Targeting Transforming Growth Factor-β in Metastasis: In Vitro and In Vivo Mechanisms , 2008 .

[222]  K. Mohammad,et al.  P48. Transforming growth factor β receptor I kinase inhibitor and bisphosphonates are additive to reduce breast cancer bone metastases , 2008 .

[223]  Iñaki F Trocóniz,et al.  Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. , 2008, European journal of cancer.

[224]  K. Schlingensiepen,et al.  Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. , 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[225]  R. Derynck,et al.  The TGF-β Family , 2008 .

[226]  M. Stuhrmann,et al.  Genetics, pathogenesis, clinical manifestation and management , 2007 .

[227]  M. Stuhrmann,et al.  Hereditary hemorrhagic telangiectasia. Genetics, pathogenesis, clinical manifestation and management. , 2007, Saudi medical journal.

[228]  Yibin Kang.  New tricks against an old foe: molecular dissection of metastasis tissue tropism in breast cancer. , 2006, Breast disease.

[229]  P. Dijke,et al.  TGF-h receptor function in the endothelium , 2005 .

[230]  I. Stamenkovic,et al.  Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival , 2004, Clinical & Experimental Metastasis.

[231]  M. Silva,et al.  Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-beta1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma. , 2004, Neoplasma.

[232]  M. Baum,et al.  Alternative mechanisms of action of anti-oestrogens , 2004, Breast Cancer Research and Treatment.

[233]  M. Reiss,et al.  Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. , 2003, Oncology research.

[234]  G. Remuzzi,et al.  J Am Soc Nephrol 14: 1816–1824, 2003 Add-On Anti–TGF- � Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat , 2022 .

[235]  P. Khaw,et al.  Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome , 2003, Gene Therapy.

[236]  C. Arteaga,et al.  Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. , 2003, Cancer research.

[237]  M. Vieth,et al.  COMBINING MEDICINAL CHEMISTRY WITH CHEMOGENOMIC AND COMPUTER-AIDED STRUCTURE-BASED DESIGN IN DEVELOPMENT OF NOVEL KINASE INHIBITORS , 2003 .

[238]  M. Hendrix,et al.  Invasion and metastasis of a mammary tumor involves TGF‐β signaling , 2001 .

[239]  A. Roberts,et al.  Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. , 2001, Advances in cancer research.

[240]  R. Hesketh,et al.  Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer. , 2001, Cancer research.

[241]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.

[242]  N. Voelkel,et al.  Transforming growth factor-beta1 induces endothelin-1 in a bovine pulmonary artery endothelial cell line and rat lungs via cAMP. , 2000, Pulmonary pharmacology & therapeutics.

[243]  L. Gold.  The role for transforming growth factor-beta (TGF-beta) in human cancer. , 1999, Critical reviews in oncogenesis.

[244]  E. Hersh,et al.  Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. , 1997, Cancer gene therapy.

[245]  B. Teicher,et al.  Transforming growth factor-β in in vivo resistance , 1996, Cancer Chemotherapy and Pharmacology.

[246]  R. Johansson,et al.  Prognostic significance of TGF-beta 1 and TGF-beta 2 expressions in female breast cancer. , 1995, Anticancer research.

[247]  M. Sporn,et al.  Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β) , 1993 .

[248]  M. Reiss,et al.  Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. , 1993, Critical reviews in oncogenesis.

[249]  M. Sporn,et al.  Localization of transforming growth factor-beta isotypes in lesions of the human breast. , 1992, Human pathology.

[250]  G. Wilding,et al.  Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. , 1991, Cancer research.

[251]  D. Welch.  Transforming growth factor β stimulates mamary adenocarcinoma cell invasion and metastasis potential , 1990 .

[252]  A. Ciampi,et al.  A Stem Cell Model of Human Tumor Growth: Implications for Tumor Cell Clonogenic Assays , 1983 .